ADAM17 and obesity disorder: The ADAM17 silencing of VAT macrophage-targeted was sufficient to reduce and alleviate visceral inflammation and improve T2DM by reducing whole-body inflammation and improving insulin resistance in an obesity-induced diabetes model [80].